May 20, 2014 by Arezu Sarvestani
Michigan medical device maker HistoSonics is creeping toward the close of a $14.22 million funding round in support of its non-invasive tissue ablation technology.
The company has raised about $14.17 million so far from 13 unnamed investors, through sales of equity, options, warrants and other rights to acquire securities, according to an SEC filing dated May 16. Read more
May 19, 2014 by Arezu Sarvestani
Israeli device maker Keystone Heart raised $14 million in a Series B funding round in support of its TriGaurd implant, designed to help protect the brain during transcatheter valve replacement procedures.
The company plans to use the funds to launch clinical trials in the U.S. and Europe to generate data in support of ongoing commercial efforts. Keystone also hired Hank Hauser as its vice president of clinical operation to oversee the trials. Read more
May 16, 2014 by Arezu Sarvestani
California-based Ceterix Orthopaedics plans to boost its marketing efforts with the help of $18 million in new financing.
The company hopes to widen the reach of its surgical tools, which help physicians place stitches in hard-to-reach places while protecting other tissue. Ceterix’s technology is currently in use by more than 100 physicians in the U.S., according to a company statement. Read more
May 21, 2014 by Arezu Sarvestani
Boston-based innovation development group Allied Minds is planning a $140 million (£83 million) initial public offering on the London Stock Exchange in support of its effort to commercialize products in the U.S.
Allied Minds CEO Chris Silva called the offering is “a major strategic step” for the firm, which in 2011 formed a medtech-focused subsidiary to develop new devices originating from U.S. universities and federally funded research institutions. Allied Minds aims to take new products from development to market in 2 years. Read more
May 22, 2014 by Arezu Sarvestani
Remote monitoring startup iRhythm touted a new $17 million Series E funding round in support of its wearable devices, saying it plans to pursue efforts in commercialization, marketing and clinical studies.
The San Francisco company offers continuous cardiac monitoring with its FDA-cleared Zio wearable device and accompanying software. The system is designed to log data on patients’ heart rhythms, then process and analyze the data to kick out a report for physicians. Read more